Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

66.53
Delayed Data
As of 3:59pm ET
 -0.53 / -0.79%
Today’s Change
54.98
Today|||52-Week Range
142.10
-38.77%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.7B

Company Description

Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Contact Information

Intercept Pharmaceuticals, Inc.
10 Hudson Yards
New York New York 10001
P:(646) 747-1000
Investor Relations:

Employees

Shareholders

Mutual fund holders58.24%
Individual stakeholders36.18%
Other institutional25.94%

Top Executives

Mark E. PruzanskiPresident, Chief Executive Officer & Director
Jerome B. DursoChief Operating Officer
Sandip S. KapadiaCFO, Treasurer & Principal Accounting Officer
David A. ShapiroChief Medical Officer
Rachel L. McMinnChief Business & Strategy Officer